NCT02348177 - Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Acquired Immunodeficiency SyndromeTuberculosis

Interventions

DRUG

lopinavir with ritonavir in 1:1 ratio

During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio

DRUG

Lopinavir/ritonavir 4:1

This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped

Trial Locations (5)

1864

Perinatal HIV Research Unit, Johannesburg

2001

Shandukani Research WRHI, Johannesburg

2093

Empilweni Services and Research Unit, Johannesburg

4013

Enhancing Care Foundation; Wendworth Hospital, Durban

7505

The Children's Infectious Disease Clinical Research Unit; University of Stellenbosch, Cape Town